Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
214
datasets available to search
ShareScore release 0.9.0
Dataset results
214 results for “Pleural mesothelioma”
A novel therapeutic strategy targeting the mesenchymal phenotype of malignant pleural mesothelioma by suppressing LSD1 [ATAC-seq]
GEO Series GSE182153. Homo sapiens. 4 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Soluble Mesothelin-Related Peptide as a Prognosticator in Pleural Mesothelioma Patients Receiving Checkpoint Immunotherapy
GEO Series GSE274983. Homo sapiens. 18 samples. Type: Expression profiling by high throughput sequencing.
Association of RERG Expression to Female Survival Advantage in Malignant Pleural Mesothelioma I
GEO Series GSE163720. Homo sapiens. 131 samples. Type: Expression profiling by array.
A novel therapeutic strategy targeting the mesenchymal phenotype of malignant pleural mesothelioma by suppressing LSD1
GEO Series GSE182154. Homo sapiens. 13 samples. Type: Expression profiling by array; Genome binding/occupancy profiling by high throughput sequencing.
Gene Expression of Malignant Pleural Mesothelioma Tumor and paired Normal Lung tissue
GEO Series GSE51024. Homo sapiens. 96 samples. Type: Expression profiling by array.
TRIM28 keeps the time of mitotic gene expression sustaining proliferation and progression of Malignant Pleural Mesothelioma (MPM).
GEO Series GSE183088. Homo sapiens. 86 samples. Type: Expression profiling by array.
Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma
GEO Series GSE223395. Homo sapiens. 20 samples. Type: Expression profiling by array.
Global gene expression profiling of human pleural mesotheliomas
GEO Series GSE12345. Homo sapiens. 13 samples. Type: Expression profiling by array.
AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma
ClinicalTrials.gov study NCT01105390. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Effect of Expression of CD74 and VEGF on Outcome of Treatment in Patients With Malignant Pleural Mesothelioma
ClinicalTrials.gov study NCT02761863. IPD Sharing: NO. Countries: 0. Publications: 0.
Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma
ClinicalTrials.gov study NCT06416930. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma
ClinicalTrials.gov study NCT04713761. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Chromosomal aberration of malignant pleural mesothelioma cell lines
GEO Series GSE22237. Homo sapiens. 14 samples. Type: Genome variation profiling by genome tiling array.
Generating Revitalized Stem Cell-Engineered CAR-NKT Cells for the Treatment of Malignant Pleural Mesothelioma
GEO Series GSE306014. Homo sapiens. 6 samples. Type: Methylation profiling by high throughput sequencing.
Generating Revitalized Stem Cell-Engineered CAR-NKT Cells for the Treatment of Malignant Pleural Mesothelioma
GEO Series GSE305915. Homo sapiens. 1 samples. Type: Expression profiling by high throughput sequencing.
Genotyping of Malignant Pleural Mesothelioma primary cell lines by SNP array
GEO Series GSE197288. Homo sapiens. 45 samples. Type: Genome variation profiling by SNP array; SNP genotyping by SNP array.
Differential gene expression profiles of side population and non-side population cells of malignant pleural mesothelioma
GEO Series GSE33734. Homo sapiens. 4 samples. Type: Expression profiling by array.
Real-time quantitative PCR analysis of human malignant pleural mesothelioma tissue specimens
GEO Series GSE54394. Homo sapiens. 15 samples. Type: Expression profiling by RT-PCR.
Dataset related to article "Volumetric Modulated Arc Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: A Single Institution Experience."
<p>INTRODUCTION:</p> <p>We investigated the possible role of volumetric modulated arc therapy (VMAT) in the setting of adjuvant treatment of malignant pleural mesothelioma (MPM) after lung-sparing surgery with pleurectomy and decortication.</p> <p>MATERIALS AND METHODS:</p> <p>Patients affected by MPM who had undergone pleurectomy and decortication and adjuvant radiotherapy with VMAT were included. The endpoints of the present analysis were local control, progression-free survival, and overall survival. Assessment of the variables affecting survival was performed using univariate and multivariate Cox proportional hazard models.</p> <p>RESULTS:</p> <p>A total of 49 patients were included in the present study. Of the 49 patients, 96% had been treated with a trimodality approach. Radiotherapy was delivered to a median dose of 44 Gy in 22 fractions (range, 22-59.4 Gy). The treatment was well tolerated, with just 2 grade 3 acute toxicities, 1 grade 5, and 2 grade 4 toxicities recorded during the follow-up period. The median follow-up period was 27.4 months. The local control rate at 12, 24, and 36 months was 75.2%, 67.4%, and 56.5%, respectively. The median progression-free survival was 14.9 months (95% confidence interval [CI], 7.5-25.2). The median overall survival was 21.5 months (95% CI, 15.3-37.1). On multivariate analysis, the administration of carboplatin- instead of cisplatin-based chemotherapy (hazard ratio, 2.97; 95% CI, 1.22-7.26; P = .017) and R2 resection (hazard ratio, 1.95; 95% CI, 1.27-2.99; P = .002) showed a negative correlation with overall survival. On univariate analysis, the percentage of the heart receiving >20 Gy and >30 was associated with the occurrence of late pneumonitis (P = .018 and P = .077).</p> <p>CONCLUSION:</p> <p>VMAT is feasible in the setting of MPM after lung-sparing surgery. The toxicity rates were reduced with this technique compared with historical data of older techniques. Local and distant failure remain a major issue to be addressed in future trials.</p>
Dataset related to article "Extended Pleurectomy/Decortication for Malignant Pleural Mesothelioma: Humanitas's Experience"
<p>This record contains raw data related to article “Extended Pleurectomy/Decortication for Malignant Pleural Mesothelioma: Humanitas's Experience"</p> <p><strong>Background: </strong> We analysed a series of malignant pleural mesothelioma (MPM) patients who consecutively underwent extended Pleurectomy/Decortication (eP/D) in a centre with a high level of thoracic surgery experience (IRCCS Humanitas Research Hospital) to explore postoperative morbidity and mortality, pattern of recurrence and survival.</p> <p><strong>Methods: </strong> A retrospective analysis was performed on MPM patients underwent eP/D in our centre from 2010 to 2021. All patients were identified from our departmental database. Postoperative complications were scored according to Clavien-Dindo criteria. Survival analysis was performed by the Kaplan-Meier methods and Cox multivariable analysis.</p> <p><strong>Results: </strong> Eighty-five patients underwent extended pleurectomy decortication (eP/D) during study period. Macroscopical residual disease (R2) was reported in one case. A neoadjuvant chemotherapy regiment was administrated in 88% of the surgical cohort. A complete trimodality treatment including induction with platinum agents and pemetrexed, radical cytoreductive surgery and volumetric modulated arc therapy technology (VMAT) could be administered in 63 patients (74%). Postoperative morbidity rate was 54.11%, major complications (defined as Clavien-Dindo ≥ 3) were reported in 11 patients (12.9%). Thirty-day mortality and 90-day mortality were, respectively, 2.35% and 3.53%. Median disease-free and overall survival were, respectively, 13.7 and 25.5 months. The occurrence of major complications (Clavien-Dindo ≥ 3), operative time, pT3-T4, pathological node involvement (pN+) were prognostic factors associated with worse survival.</p> <p><strong>Conclusions: </strong> In our experience, eP/D is a well-tolerated procedure with acceptable mortality and morbidity, allowing for the administration of trimodality regimens in most patients. eP/D offered in a multimodality treatment setting have satisfactory long term oncological results. To obtain best oncological results the goal of surgery should be macroscopic complete resection in carefully selected patients (clinical N0).</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.